The FDA has approved Spiriva Respimat (tiotropium bromide, Boehringer Ingelheim), a steroid-free inhalation spray, for the long-term, once-daily maintenance treatment of asthma in patients 6 years of age and older. The agency approved the supplemental new drug application under a priority review designation.
Spiriva Respimat, which is delivered as two puffs once a day of 1.25 mcg per puff, is the only long-acting muscarinic antagonist (LAMA) product indicated for asthma. It was originally approved in September 2015 for the long-term, once-daily maintenance treatment of asthma in patients12 years of age and older.
The new approval was based on efficacy and safety data from the phase 2 and phase 3 UniTinA-asthma clinical development program, which included more than 6,000 patients worldwide, including 804 children (6 to 11 years of age).
More than 24 million people have asthma in the United States, including 6.3 million children younger than 18 years of age. Many children and adults continue to have uncontrolled asthma despite taking maintenance treatments. According to the Centers for Disease Control and Prevention, 50% of adults and more than 38% of children with asthma in the U.S. remain symptomatic despite maintenance treatment.
Source: Boehringer Ingelheim(link is external); February 16, 2017.
More Headlines
READ NEXT
FiercePharma has compiled a list of the top 15 cancer medications that are expected to dominate the oncology market in 2022.
Joint Venture Health Plans May Give ACOs a Run for Their Money
Joint venture plans are starting to demonstrate their ability to implement clinical management and financial management reforms. A JV health plan replaces the offloading of financial risk by health plans to ill-equipped providers with an executive-level cost management committee stated jointly by the hospital and payer.
Fake Doctor Roams Boston Hospital
For several days, a middle-aged woman who claimed to be a doctor in training roamed the halls of Brigham and Women’s Hospital in Boston, dressed in scrubs, asking questions at a lecture, attending patient rounds, and observing surgical procedures, according to a report in the Boston Globe

Paul Lendner ist ein praktizierender Experte im Bereich Gesundheit, Medizin und Fitness. Er schreibt bereits seit über 5 Jahren für das Managed Care Mag. Mit seinen Artikeln, die einen einzigartigen Expertenstatus nachweisen, liefert er unseren Lesern nicht nur Mehrwert, sondern auch Hilfestellung bei ihren Problemen.